THE POTENT oncogenic compound ethylnitrosourea (ENU) selectively induces a high incidence of neurogenic neoplasms in the offspring of pregnant rats after i.v. administration late in gestation (Ivankovic & Druckrey, 1968; Koestner et al., 1971) . The ENU-treated offspring survive a latency period of 100 to several hundred days and then succumb either to malignant gliomas of the brain or spinal cord, or to malignant Schwannomas located predominantly in Cranial Nerve V or spinal nerve roots. Whether these gliomas and Schwannomas are immunogenic, and whether the gliomas, located in the relativelv immunologically privileged brain (Scheinberg et al., 1964 (Scheinberg et al., , 1965 are protected from immune surveillance comprise two questions pertaining to the role of immunity in the pathogenesis of brain tumours. Among several experimental approaches to these questions, one consists of immunizing against carcinogenesis (Prehn, 1961) i.e., inoculating the offspring of ENU-treated rats with glioma or Schwannoma antigens to determine whether this type of immunization increases the lifespan, or reduces the incidence of tumours, in susceptible animals. The Table I .
The glioma-cell immunizing inocula administered to Group I rats were prepared from 4 separate ENU-induced syngeneic glioma lines, previously generated in our laboratory by the alternate culture and transplantation method (Benda et al., 1971) . These glioma lines originated from a cerebral glioblastoma multiforme, a cerebral mixed oligodendroglioma-astrocytoma, and 2 astrocytomas, one cerebral and the other from spinal cord. Earlygeneration stocks of the 4 glioma lines maintained in vitro in Waymouth's medium (Hellstrom & Hellstrom, 1971) were washed wvith phosphate-buffered (Denlinger et al., 1973) . Within the individual groups the meani lifespan, the mean number of gliomas or Schwannomas per rat, and the mean of the total number of tumours per rat were calculated. Among all the immunization groups the means of these 4 variables w-ere assessed for statistically significant differences by an unweighted analysis of variance, retaining sex as a second factor.
The results are presented in Table 11 . XVith respect to lifespan, number of gliomas or number of Schwannomas per rat, or total number of tumours per rat, there were no differences among Groups I-VI, no differences attributable to sex, and no significant interaction between sex and groups; that is, the various immunization procedures were all without significant effect on the outcome of ENU neurooncogenesis under the conditions of this experiment. The mean number of Schwannomas per rat was greater in the 90 males (0.69) than in the 91 females (0.43) (P<0 01 by analysis of variance). Although the mean lifespan (226 days) and mean number of gliomas per rat (1.30) in the entire group of males were less than in females (246 days and 1 58 gliomas respectively), these differences were not statistically significant.
In the whole series of 181 rats, 20 nonneurogenic tumours were also noted: 6 renal, 4 small bowel, 2 lung, 2 breast, 2 mediastinal, 1 urinary bladder, 1 intracranial meninges, 1 pituitary, and 1 testis. These were randomly distributed among the various groups.
That no immunological effect on ENU neuro-oncogenesis was detected in the present study is probably explained by the following considerations. First, with few exceptions chemically induced immunogenic neoplasms express individually unique rather than cross-reacting transplantation antigens (Herberman, 1977) . Although some investigators have demonstrated cross-reacting antigens shared among certain chemically induced experimental tumours (Reiner & Southam, 1967; Steele & Sjogren, 1974; Hellstrom et al., 1978) such antigens probably do not play a dominant role in eliciting tumoricidal immunity in vivo (Hellstrom & Brown, 1979) . It is unlikely, therefore, that our immunizing preparations, despite being derived from several tumours, contained major immunogenic constituents in common with the ENU-induced neoplasms that arose in our immunized rats. Second, regarding the gliomas, their location within the relatively immunologically privileged CNS parenchyma (Scheinberg et al., 1964 (Scheinberg et al., , 1965 probably protected them from exposure to cellular and humoral immune elements. Third, the carcinogenic action of ENU takes place late in foetal development, a time at which immunological tolerance to potential tumour-associated transplantation antigens could evolve. Fourth, our methods may not have presented sufficient antigenic material to induce effective immunity in the tumourdeveloping rats. Fifth, since many chemical carcinogens including methylnitrosourea, which is closely related to ENU (Parmiani et al., 1971 ) display immuno-suppressive activity, there is a distinct possibility that ENU vitiated the capacity of host animals to respond immunologically to tumour development. Sixth, the immunogenicity of ENU-induced tumours may be so weak as to be undetectable.
To what degree these factors individually affected our experimental results is open to speculation. All probably contributed but, in our view, the immunogenicity of ENU-induced rat tumours is the most important consideration. Rainbird & Ridley (1977) evaluated the immunogenic strength of 6 ENU-induced rat Schwannomas in in vivo tumourrejection assays (Sjogren, 1965) and determined that only 1 of these 6 Schwannomas was immunogenic. On the other hand, Cornain et al. (1975) claimed to have demonstrated with similar methods that 2 ENU-induced rat tumours, one glioma and one Schwannoma, both manifested low immunogenicity. However, no supporting data from in vivo tests accompanied this claim. In our laboratory, ongoing investigations of this type have revealed that only 1 of 5 ENU-induced gliomas elicits detectable transplantation immunity in vivo (unpublished observations). In concert with the findings on Schwannomas (Rainbird & Ridley, 1977) these observations suggest that the incidence of tumour-rejection antigens in transplantable ENU-induced neurogenic tumours, gliomas as well as Schwannomas, is low. It is likely that the incidence of such antigens is similarly low in autochthonous ENU-induced gliomas and Schwannomas, indeed, low enough to explain adequately why the immunological measures reported in this communication influenced neither the latency nor the incidence of tumours in ENU neuro-oncogenesis in the rat.
